<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2012-5-71-73</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-1922</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МНЕНИЕ ПО ПРОБЛЕМЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>OPINION ON A PROBLEM</subject></subj-group></article-categories><title-group><article-title>Эналаприл: новые возможности</article-title><trans-title-group xml:lang="en"><trans-title>Enalapril: new possibilities</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Таратухин</surname><given-names>Е. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Taratukhin</surname><given-names>E. O.</given-names></name></name-alternatives><bio xml:lang="ru"/><email xlink:type="simple">cardio03@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Российский научно-исследовательский медицинский университет им. Н.И. Пирогова, Москва<country>Россия</country></aff><aff xml:lang="en">N.I. Pirogov Russian Research Medical University, Moscow<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>20</day><month>10</month><year>2012</year></pub-date><volume>11</volume><issue>5</issue><fpage>71</fpage><lpage>73</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Таратухин Е.О., 2012</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="ru">Таратухин Е.О.</copyright-holder><copyright-holder xml:lang="en">Taratukhin E.O.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/1922">https://cardiovascular.elpub.ru/jour/article/view/1922</self-uri><abstract><p>В обзоре представлены данные современных исследований эналаприла, открывающие новые свойства этого препарата, расширяющие представление о его лечебном эффекте.</p></abstract><trans-abstract xml:lang="en"/><kwd-group xml:lang="ru"><kwd>артериальная гипертензия</kwd><kwd>сердечная недостаточность</kwd><kwd>ангиотензин-превращающий фермент</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension</kwd><kwd>heart failure</kwd><kwd>angiotensin-converting enzyme</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Katzung BG. Basic and clinical pharmacology. 10th ed. McGrawHill 2007; 1179c.</mixed-citation><mixed-citation xml:lang="en">Katzung BG. Basic and clinical pharmacology. 10th ed. McGrawHill 2007; 1179c.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ma J, Lee K-V, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension. Hypertension 2006; 48: 846-52.</mixed-citation><mixed-citation xml:lang="en">Ma J, Lee K-V, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension. Hypertension 2006; 48: 846-52.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Nair AP, Timoh T, Fuster V. Contemporary medical management of systolic heart failure. Circulation J 2012; 76: 268-77.</mixed-citation><mixed-citation xml:lang="en">Nair AP, Timoh T, Fuster V. Contemporary medical management of systolic heart failure. Circulation J 2012; 76: 268-77.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with ACE inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348(7): 583-92.</mixed-citation><mixed-citation xml:lang="en">Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with ACE inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348(7): 583-92.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Nissen SE, Tuzcu EM, Libbi P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: a randomized controlled trial. JAMA 2004; 292: 2217-25.</mixed-citation><mixed-citation xml:lang="en">Nissen SE, Tuzcu EM, Libbi P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: a randomized controlled trial. JAMA 2004; 292: 2217-25.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of longstanding persistent atrial fibrillation: results of prospective and controlled study. Eur Heart J 2003; 24: 2090-8.</mixed-citation><mixed-citation xml:lang="en">Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of longstanding persistent atrial fibrillation: results of prospective and controlled study. Eur Heart J 2003; 24: 2090-8.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Chen JL, Shang QH, Hu W, et al. Role of TGF/Smads pathway in carotid artery remodeling in renovascular hypertensive rats and prevention by enalapril and amlodipine. J Geriatr Cardiol 2012; 9: 185-91.</mixed-citation><mixed-citation xml:lang="en">Chen JL, Shang QH, Hu W, et al. Role of TGF/Smads pathway in carotid artery remodeling in renovascular hypertensive rats and prevention by enalapril and amlodipine. J Geriatr Cardiol 2012; 9: 185-91.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Bosch X, Esteve J, Sitges M, et al. Prevention of chemotherapy-induced LV dysfunction woth enalapril and carvedilol: rationale and design of the OVERCOME trial. J Card Fail 2011; 17: 643-8.</mixed-citation><mixed-citation xml:lang="en">Bosch X, Esteve J, Sitges M, et al. Prevention of chemotherapy-induced LV dysfunction woth enalapril and carvedilol: rationale and design of the OVERCOME trial. J Card Fail 2011; 17: 643-8.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Krysiak R, Okopieá B. Lymphocyte-suppressing action of angiotensin-converting enzyme inhibitors in coronary artery disease patients with normal BP. Pharmacol Rep 2011; 63: 1151-61.</mixed-citation><mixed-citation xml:lang="en">Krysiak R, Okopieá B. Lymphocyte-suppressing action of angiotensin-converting enzyme inhibitors in coronary artery disease patients with normal BP. Pharmacol Rep 2011; 63: 1151-61.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Funck-Brentano C, van Veldhuisen DJ, van de Ven LL, et al. Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. Eur J Heart Fail 2011; 13: 765-72.</mixed-citation><mixed-citation xml:lang="en">Funck-Brentano C, van Veldhuisen DJ, van de Ven LL, et al. Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. Eur J Heart Fail 2011; 13: 765-72.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Cacciatore F, Bruzzese G, Vitale DF, et al. Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage and oxidative stress in hypertensive patients. Eur J Clin Pharmacol 2011; 67: 877-93.</mixed-citation><mixed-citation xml:lang="en">Cacciatore F, Bruzzese G, Vitale DF, et al. Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage and oxidative stress in hypertensive patients. Eur J Clin Pharmacol 2011; 67: 877-93.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Georgakopoulous P, Roussou P, Matsakas E, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients. Am J Hematol 2010; 85: 894-6.</mixed-citation><mixed-citation xml:lang="en">Georgakopoulous P, Roussou P, Matsakas E, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients. Am J Hematol 2010; 85: 894-6.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zou D, Grote L, Eder DN, et al. A double-blind, crossover study of doxazosin and enalapril on peripheral vascular tone and nocturnal BP in sleep apnea patients. Sleep Med 2010; 11: 325-8.</mixed-citation><mixed-citation xml:lang="en">Zou D, Grote L, Eder DN, et al. A double-blind, crossover study of doxazosin and enalapril on peripheral vascular tone and nocturnal BP in sleep apnea patients. Sleep Med 2010; 11: 325-8.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hoque R, Rahman MS, Iqbal M, et al. Effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients. Bangl Med Res Counc Bull 2009; 35: 44-8.</mixed-citation><mixed-citation xml:lang="en">Hoque R, Rahman MS, Iqbal M, et al. Effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients. Bangl Med Res Counc Bull 2009; 35: 44-8.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in pype 1 diabetes. N Engl J Med 2009; 361: 40-51.</mixed-citation><mixed-citation xml:lang="en">Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in pype 1 diabetes. N Engl J Med 2009; 361: 40-51.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Purclutepe O, Iskender G, Kiper HD, et al. Enalapril-induced apoptosis of acute promyelocytic leukaemia cells involves STAT5A. Anticancer Res 2012; 32: 2885-93.</mixed-citation><mixed-citation xml:lang="en">Purclutepe O, Iskender G, Kiper HD, et al. Enalapril-induced apoptosis of acute promyelocytic leukaemia cells involves STAT5A. Anticancer Res 2012; 32: 2885-93.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Hale TM, Robertson SJ, Burns KD, et al. Short-term ACE inhibition confers longterm protection against target organ damage. Hypertens Res 2012; 35: 604-10.</mixed-citation><mixed-citation xml:lang="en">Hale TM, Robertson SJ, Burns KD, et al. Short-term ACE inhibition confers longterm protection against target organ damage. Hypertens Res 2012; 35: 604-10.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Bowling CB, Sanders PW, Allman RM, et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease. Int J Cardiol 2012; Jan 16. (в печати).</mixed-citation><mixed-citation xml:lang="en">Bowling CB, Sanders PW, Allman RM, et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease. Int J Cardiol 2012; Jan 16. (в печати).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Silva PS, Fontana V, Luizon MR, et al. eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril. Eur J Clin Pharmacol 2012; Jun, 17. (в печати).</mixed-citation><mixed-citation xml:lang="en">Silva PS, Fontana V, Luizon MR, et al. eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril. Eur J Clin Pharmacol 2012; Jun, 17. (в печати).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Perkins BA, Sochett EB, Cherney DZ. Ability of cystatin C to detect changes in glomerular filtration rate after ACE inhibition in patients with uncomplicated type 1 diabetes. Clin Exp Hypertens 2012; Jun,11. (в печати).</mixed-citation><mixed-citation xml:lang="en">Perkins BA, Sochett EB, Cherney DZ. Ability of cystatin C to detect changes in glomerular filtration rate after ACE inhibition in patients with uncomplicated type 1 diabetes. Clin Exp Hypertens 2012; Jun,11. (в печати).</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Velez Rueda JO, Palomeque J, Mattiazzi A, et al. Early apoptosis in different models of cardiac hypertrophy induced by high renin-angiotensinsystem activity involves CaMKII. J Appl Physiol 2012; 112: 2110-20.</mixed-citation><mixed-citation xml:lang="en">Velez Rueda JO, Palomeque J, Mattiazzi A, et al. Early apoptosis in different models of cardiac hypertrophy induced by high renin-angiotensinsystem activity involves CaMKII. J Appl Physiol 2012; 112: 2110-20.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Taddei S. Fixed-dose combination therapy in hypertension. High Blood Pres 2012; 19(2): 55-7.</mixed-citation><mixed-citation xml:lang="en">Taddei S. Fixed-dose combination therapy in hypertension. High Blood Pres 2012; 19(2): 55-7.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Aronow WS. Treatment of systemic hypertension. Am J Cardiovasc Dis 2012; 2(3): 160-70.</mixed-citation><mixed-citation xml:lang="en">Aronow WS. Treatment of systemic hypertension. Am J Cardiovasc Dis 2012; 2(3): 160-70.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Chobanian AV, Bakris GL, Black HR, et al. National HLB Institute JNC on prevention, detection, evaluation and treatment of High Blood Pressure. The Seventh report of the National Comittee. JAMA 2003; 289: 2560-72.</mixed-citation><mixed-citation xml:lang="en">Chobanian AV, Bakris GL, Black HR, et al. National HLB Institute JNC on prevention, detection, evaluation and treatment of High Blood Pressure. The Seventh report of the National Comittee. JAMA 2003; 289: 2560-72.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Peterzan MA, Hardy R, Chaturvedi N, et al. Meta-Analysis of DoseResponse Relationships for Hydrochlorothiazide, Chlorthalidone and Bendroflumethiazide on blood Pressure, serum Potassium and Urate. Hypertension 2012; 59: 1104-9.</mixed-citation><mixed-citation xml:lang="en">Peterzan MA, Hardy R, Chaturvedi N, et al. Meta-Analysis of DoseResponse Relationships for Hydrochlorothiazide, Chlorthalidone and Bendroflumethiazide on blood Pressure, serum Potassium and Urate. Hypertension 2012; 59: 1104-9.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
